Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

John F. Seymour, Jenny Qun Wu, Relja Popovic, Barbara Eichhorst, Peter Hillmen, Thomas J. Kipps, Anton W. Langerak, Carolyn Owen, Julie Dubois, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Fengjiao Dunbar, Yanwen Jiang, Brenda Chyla, Michelle Boyer, Maria Thadani-Mulero, Marcus Lefebure, Rosemary Harrup, Arnon P. Kater

Blood (2021) 138 (Supplement 1): 1548.

https://doi.org/10.1182/blood-2021-147731

Published: 2021

Journal Articles

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Blood (2021) 138 (Supplement 1): 241.

https://doi.org/10.1182/blood-2021-145613

Published: 2021

Journal Articles

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

Brenda J Chyla, PhD, Relja Popovic, PhD, Charles Lu, PhD, Fengjiao Dunbar, PhD, Danjuma Quarless, PhD, Kenneth Robinson, MS, Scott Warder, PhD, Amanda Jacobson, PhD, Lang Zhou, PhD, Andrew Souers, PhD, Jeffrey Waring, PhD, Anahita Bhathena, PhD, Joel D. Leverson, PhD, Su Young Kim, MD PhD

Blood (2019) 134 (Supplement_1): 172.

https://doi.org/10.1182/blood-2019-127458

Published: 2019

Journal Articles

5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis

Dan Cojocari, PhD BSc, Sha Jin, MS, Julie J Purkal, MA, Relja Popovic, PhD, Nari N Talaty, PhD, Yu Xiao, MS, Larry R Solomon, PhD, Erwin Boghaert, MS, MD, Joel D. Leverson, PhD, Darren C. Phillips, PhD

Blood (2018) 132 (Supplement 1): 2644.

https://doi.org/10.1182/blood-2018-99-111985

Published: 2018

Journal Articles

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Andrew Wei, MD, Stephen A. Strickland, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L Lin, MD, Roland B. Walter, MDPhDMS, Anoop K Enjeti, MBBS,FRCPA,MDMRCP, Wan-Jen Hong, Brenda Chyla, Relja Popovic, PhD, Kaffa Fakouhi, Tu Xu, PhD, John Hayslip, Gail J. Roboz, MD

Blood (2018) 132 (Supplement 1): 284.

https://doi.org/10.1182/blood-2018-99-118729

Published: 2018

Journal Articles

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Andrew Wei, MBBS, PhD FRACP, FRCPA, Stephen A. Strickland, MD MSCI, Gail J. Roboz, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L. Lin, MD, Roland B. Walter, MD PhD, Anoop Enjeti, MD MRCP, FRCPA, MClin Epid, GradCert Bioethics, Brenda Chyla, PhD, Relja Popovic, PhD, Kaffa Fakouhi, Pooja Shah, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, John Hayslip, MD MSCR

Blood (2017) 130 (Supplement 1): 890.

https://doi.org/10.1182/blood.V130.Suppl_1.890.890

Published: 2017

Journal Articles

Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia

Brenda Chyla, Relja Popovic, Jalaja Potluri, John Hayslip, Xin Huang, Ming Zhu, Mack Mabry, Anahita Bhathena

Blood (2016) 128 (22): 1709.

https://doi.org/10.1182/blood.V128.22.1709.1709

Published: 2016

Journal Articles

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Andrew W. Roberts, John F Seymour, Barbara Eichhorst, MD, Stephan Stilgenbauer, Michael Y. Choi, MD, Matthew S. Davids, John F. Gerecitano, Relja Popovic, Brenda Chyla, Ming Zhu, Maria Verdugo, Jalaja Potluri, Leanne Lash, Su Young Kim, Michael Hallek

Blood (2016) 128 (22): 3230.

https://doi.org/10.1182/blood.V128.22.3230.3230

Published: 2016

Journal Articles

Allele-Specific Crispr Targeting Reveals Epigenetic and Phenotypic Effects of a MMSET Gain of Function Mutation Found in Relapsed Acute Lymphoblastic Leukemia

Jon Oyer, PhD, Christine Will, M.S., Xiaoxiao Huang, Teresa Ezponda, PhD, Relja Popovic, PhD, Yupeng Zheng, PhD, Neil L Kelleher, PhD, Jonathan D. Licht, MD

Blood (2015) 126 (23): 437.

https://doi.org/10.1182/blood.V126.23.437.437

Published: 2015

Journal Articles

Loss of the Histone Demethylase UTX Contributes to Multiple Myeloma and Sensitizes Cells to EZH2 Inhibitors

Teresa Ezponda, PhD, Relja Popovic, PhD, Yupeng Zheng, PhD, Behnam Nabet, Christine Will, MS, Eliza C Small, PhD, Manuela Occhionorelli, PhD, Giovanni Tonon, MDPhD, Jonathan J. Keats, PhD, Neil L Kelleher, PhD, Jonathan D. Licht

Blood (2014) 124 (21): 611.

https://doi.org/10.1182/blood.V124.21.611.611

Published: 2014

Journal Articles

MMSET/WHSC1 Enhances DNA Damage Repair Leading To An Increase In Resistance To Chemotherapeutic Agents

Mrinal Y. Shah, PhD, Eva Martinez, PhD, Relja Popovic, PhD, Teresa Ezponda, PhD, Eliza C. Small, PhD, Christine Will, MS, Paola Neri, MD, PhD, Nizar J. Bahlis, MD, Jonathan D. Licht, MD

Blood (2013) 122 (21): 808.

https://doi.org/10.1182/blood.V122.21.808.808

Published: 2013

Journal Articles

MMSET Dysregulates Gene Expression in Myeloma Through Global and Focal Changes in H3K36 and H3K27 Methylation

Relja Popovic, PhD, Eva Martinez, PhD, Quanwei Zhang, PhD, Teresa Ezponda, PhD, Yanwen Jiang, PhD, Mrinal Y. Shah, PhD, Christine Will, M.S., Eliza C. Small, PhD, Olivier Elemento, PhD, Ji-Ping Wang, PhD, Jonathan D. Licht, MD

Blood (2012) 120 (21): 523.

https://doi.org/10.1182/blood.V120.21.523.523

Published: 2012

Journal Articles

MMSET Stimulates Myeloma Cell Growth Through MicroRNA-Mediated Modulation of c-MYC

Dong-Joon Min, PhD, Marianne Kim, PhD, Teresa Ezponda, PhD, Christine Will, M.S., Eva Martinez-Garcia, PhD, Relja Popovic, PhD, Kojo S.J. Elenitoba-Johnson, MD, Basrur Venkatesha, PhD, Jonathan D. Licht, MD

Blood (2011) 118 (21): 469.

https://doi.org/10.1182/blood.V118.21.469.469

Published: 2011

Journal Articles

MMSET Contributes to Multiple Myeloma Oncogenesis Through Induction of Global Epigenetic Changes and Alteration of the DNA Damage Response,

Relja Popovic, PhD, Eva Martinez-Garcia, PhD, Steve M.M Sweet, PhD, Yupeng Zheng, PhD, Neil L Kelleher, PhD, Jonathan D. Licht, MD

Blood (2011) 118 (21): 3475.

https://doi.org/10.1182/blood.V118.21.3475.3475

Published: 2011

Journal Articles

MEK and MAF in myeloma therapy

Relja Popovic, Jonathan D. Licht

Blood (2011) 117 (8): 2300–2302.

https://doi.org/10.1182/blood-2011-01-327262

Published: 2011

Journal Articles

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells

Eva Martinez-Garcia, Relja Popovic, Dong-Joon Min, Steve M. M. Sweet, Paul M. Thomas, Leonid Zamdborg, Aaron Heffner, Christine Will, Laurence Lamy, Louis M. Staudt, David L. Levens, Neil L. Kelleher, Jonathan D. Licht

Blood (2011) 117 (1): 211–220.

https://doi.org/10.1182/blood-2010-07-298349

Published: 2011

Includes: Supplemental data

Journal Articles

The MMSET Histone Methyl Transferase Alters Chromatin Structure and Gene Expression in t(4;14) Multiple Myeloma Cells.

Eva Martinez-Garcia, PhD, Relja Popovic, PhD, Dong-Joon Min, PhD, Christine Will, MS, Julia Meyer, BS, Louis M. Staudt, MD, PhD, Laurence Lamy, PhD, Josh Lauring, MD, PhD, Zhongjun Cheng, PhD, Dinshaw Patel, PhD, Jonathan D. Licht, M.D.

Blood (2009) 114 (22): 675.

https://doi.org/10.1182/blood.V114.22.675.675

Published: 2009

Journal Articles

Structural Basis for MLL Cxxc Domain Protection against CpG DNA Methylation and the Essential Role of This Function in MLL-AF9 Leukemia.

Laurie Risner, Tomasz Cierpicki, PhD, Jolanta Grembecka, PhD, Stephen M Lukasik, PhD, Relja Popovic, PhD, David S Shultis, PhD, Nancy J. Zeleznik-Le, PhD, John H. Bushweller, PhD

Blood (2009) 114 (22): 763.

https://doi.org/10.1182/blood.V114.22.763.763

Published: 2009

Journal Articles

Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization

Relja Popovic, Laurie E. Riesbeck, Chinavenmeni S. Velu, Aditya Chaubey, Jiwang Zhang, Nicholas J. Achille, Frank E. Erfurth, Katherine Eaton, Jun Lu, H. Leighton Grimes, Jianjun Chen, Janet D. Rowley, Nancy J. Zeleznik-Le

Blood (2009) 113 (14): 3314–3322.

https://doi.org/10.1182/blood-2008-04-154310

Published: 2009

Journal Articles

MLL-AF4 Down-Regulates CDKN1B (P27) Independent of Cell Cycle Progression.

Zhenbiao Xia, MD, Relja Popovic, BS, Tara Lorenz, Donna Santillan, BS, BA, Frank Erfurth, Ph.D, Nancy J. Zeleznik-Le, Ph.D

Blood (2004) 104 (11): 2563.

https://doi.org/10.1182/blood.V104.11.2563.2563

Published: 2004

NARROW

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis

Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Allele-Specific Crispr Targeting Reveals Epigenetic and Phenotypic Effects of a MMSET Gain of Function Mutation Found in Relapsed Acute Lymphoblastic Leukemia

Loss of the Histone Demethylase UTX Contributes to Multiple Myeloma and Sensitizes Cells to EZH2 Inhibitors

MMSET/WHSC1 Enhances DNA Damage Repair Leading To An Increase In Resistance To Chemotherapeutic Agents

MMSET Dysregulates Gene Expression in Myeloma Through Global and Focal Changes in H3K36 and H3K27 Methylation

MMSET Stimulates Myeloma Cell Growth Through MicroRNA-Mediated Modulation of c-MYC

MMSET Contributes to Multiple Myeloma Oncogenesis Through Induction of Global Epigenetic Changes and Alteration of the DNA Damage Response,

MEK and MAF in myeloma therapy

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells

The MMSET Histone Methyl Transferase Alters Chromatin Structure and Gene Expression in t(4;14) Multiple Myeloma Cells.

Structural Basis for MLL Cxxc Domain Protection against CpG DNA Methylation and the Essential Role of This Function in MLL-AF9 Leukemia.

Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization

MLL-AF4 Down-Regulates CDKN1B (P27) Independent of Cell Cycle Progression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only